Something of a rumble is shaping up in opioid-induced bowel dysfunction, as a pair of companies race to get a drug on the market for the condition. (BioWorld Financial Watch)
It's one down, one to go for Amylin Pharmaceuticals Inc., which won a hard-fought approval by the FDA of injectable Symlin (pramlintide acetate) for patients with Type I or Type II diabetes, whose insulin is not giving them glucose control. (BioWorld Today)
Metabasis Therapeutics Inc.'s overseas partner Sankyo Co. Ltd. pulled the plug on a pair of studies with CS-917, the glucose pathway inhibitor for diabetes, after two serious averse events apparently involving potentially fatal lactic acidosis. (BioWorld Today)
